FDA Rejects Autism Label for Leucovorin
What happened
The FDA declined to approve leucovorin as a treatment for autism, despite earlier suggestions of label expansion, but approved it for cerebral folate deficiency.
Why it matters
The FDA's decision contradicts earlier statements suggesting leucovorin could benefit many autistic children. In September 2025, officials indicated the drug would be more widely available for autism. This led to a surge in prescriptions, making the drug harder to find. The approval is specifically for cerebral folate deficiency (CFD) in patients with a confirmed variant in the FOLR1 gene. This affects fewer than 1 in a million people. CFD is a neurological condition where the brain doesn't get enough folate. Some experts, like those at the Autism Science Foundation, maintain there's no solid evidence leucovorin is safe or effective for most autistic individuals. The American Academy of Pediatrics does not recommend routine use of leucovorin for autistic children. One study that supported the drug's use for autism was even retracted earlier in 2026. Despite the rejection for autism, leucovorin has shown an 87% clinical response rate in CFD-FOLR1 patients, with normalization in folate levels in the cerebral spinal fluid. Leucovorin can cross the blood-brain barrier, addressing folate deficiency in the central nervous system. Symptoms of CFD can overlap with autism, including challenges with social communication, sensory processing, and repetitive behaviors.
Key numbers
- In September 2025, officials indicated the drug would be more widely available for autism.
- The approval is specifically for cerebral folate deficiency (CFD) in patients with a confirmed variant in the FOLR1 gene.
- This affects fewer than 1 in a million people.
- One study that supported the drug's use for autism was even retracted earlier in 2026.
What happens next
- The FDA's decision contradicts earlier statements suggesting leucovorin could benefit many autistic children.
Sources
Quick answers
What happened in FDA Rejects Autism Label for Leucovorin?
The FDA declined to approve leucovorin as a treatment for autism, despite earlier suggestions of label expansion, but approved it for cerebral folate deficiency.
Why does FDA Rejects Autism Label for Leucovorin matter?
The FDA's decision contradicts earlier statements suggesting leucovorin could benefit many autistic children. In September 2025, officials indicated the drug would be more widely available for autism. This led to a surge in prescriptions, making the drug harder to find. The approval is specifically for cerebral folate deficiency (CFD) in patients with a confirmed variant in the FOLR1 gene. This affects fewer than 1 in a million people. CFD is a neurological condition where the brain doesn't get enough folate. Some experts, like those at the Autism Science Foundation, maintain there's no solid evidence leucovorin is safe or effective for most autistic individuals. The American Academy of Pediatrics does not recommend routine use of leucovorin for autistic children. One study that supported the drug's use for autism was even retracted earlier in 2026. Despite the rejection for autism, leucovorin has shown an 87% clinical response rate in CFD-FOLR1 patients, with normalization in folate levels in the cerebral spinal fluid. Leucovorin can cross the blood-brain barrier, addressing folate deficiency in the central nervous system. Symptoms of CFD can overlap with autism, including challenges with social communication, sensory processing, and repetitive behaviors.
